as 01-22-2025 4:00pm EST
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | NEW YORK |
Market Cap: | 24.5M | IPO Year: | 2019 |
Target Price: | $10.67 | AVG Volume (30 days): | 266.1K |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -3.55 | EPS Growth: | N/A |
52 Week Low/High: | $1.72 - $10.50 | Next Earning Date: | 03-21-2025 |
Revenue: | $49,999,000 | Revenue Growth: | 143.30% |
Revenue Growth (this year): | 148.8% | Revenue Growth (next year): | -60.79% |
HOOK Breaking Stock News: Dive into HOOK Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
GlobeNewswire
13 days ago
GlobeNewswire
14 days ago
GlobeNewswire
15 days ago
GlobeNewswire
16 days ago
GlobeNewswire
17 days ago
MT Newswires
21 days ago
GlobeNewswire
21 days ago
The information presented on this page, "HOOK HOOKIPA Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.